0001209191-17-053691.txt : 20170922 0001209191-17-053691.hdr.sgml : 20170922 20170922160442 ACCESSION NUMBER: 0001209191-17-053691 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170920 FILED AS OF DATE: 20170922 DATE AS OF CHANGE: 20170922 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RINGO WILLIAM R CENTRAL INDEX KEY: 0001238325 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 171097698 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-09-20 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001238325 RINGO WILLIAM R C/O SANGAMO THERAPEUTICS, INC. POINT RICHMOND TECH CTR, 501 CANAL BLVD. RICHMOND CA 94804 1 0 0 0 Common Stock 2017-09-20 4 M 0 31000 6.05 A 31800 D Common Stock 2017-09-20 4 S 0 31000 14.3741 D 800 D Stock Option (Right to Buy) 6.05 2017-09-20 4 M 0 31000 0.00 D 2020-04-15 Common Stock 31000 0 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.25 to $14.55, inclusive. The Reporting Person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The shares underlying the stock option are fully vested and exercisable. /s/ Florence Tam, Attorney-in-Fact 2017-09-22